Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

被引：6

作者：

Sakai, H. ^{[1
]}

Nishio, M. ^{[2
]}

Hida, T. ^{[3
]}

Nakagawa, K. ^{[4
]}

Nogami, N. ^{[5
]}

Atagi, S. ^{[6
]}

Takahashi, T. ^{[7
]}

Nokihara, H. ^{[8
]}

Saka, H. ^{[9
]}

Takenoyama, M. ^{[10
]}

Fujita, S. ^{[11
]}

Tanaka, H. ^{[12
]}

Takeda, K. ^{[13
]}

Satouchi, M. ^{[14
]}

Isobe, H. ^{[15
]}

Maemondo, M. ^{[16
]}

Goto, K. ^{[17
]}

Hirashima, T. ^{[18
]}

Minato, K. ^{[19
]}

Tamura, T. ^{[20
]}

机构：

[1] Saitama Canc Ctr, Thorac Oncol, Saitama, Japan

[2] Japanese Fdn Canc Res, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan

[3] Aichi Canc Ctr Hosp, Thorac Oocol, Nagoya, Aichi 464, Japan

[4] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan

[5] Natl Hosp Org, Thorac Oncol, Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Thorac Oncol, Osaka, Japan

[7] Shizuoka Canc Ctr, Thorac Oncol, Shizuoka, Japan

[8] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[9] Natl Hosp Org, Resp Med & Med Oncol, Nagoya Med Ctr, Nagoya, Aichi, Japan

[10] Kyushu Natl Canc Ctr, Thorac Oncol, Fukuoka, Japan

[11] Inst Biomed Res & Innovat, Integrated Oncol, Kobe, Hyogo, Japan

[12] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan

[13] Osaka City Gen Hosp, Med Oncol, Osaka, Japan

[14] Hyogo Canc Ctr, Thorac Oncol, Akashi, Hyogo, Japan

[15] KKR Sapporo Med Ctr, Med Oncol, Sapporo, Hokkaido, Japan

[16] Miyagi Canc Ctr, Resp Med, Natori, Miyagi 9811293, Japan

[17] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan

[18] Osaka Prefectural Med Ctr Resp & Allerg Dis, Thorac Malignancy, Osaka, Japan

[19] Gunma Prefectural Canc Ctr, Resp Med, Ohta, Gunma, Japan

[20] St Lukes Int Hosp, Thorac Canc, Tokyo, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30322-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

521

引用

页码：S110 / S111

页数：2

共 50 条

[31] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
Cho, E. K.
Kang, J. H.
Han, J-Y.
Lee, J. S.
Kim, D-W.
Kim, S-W.
Min, Y. J.
Lee, K. H.
Kim, J-H.
Park, K.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[32] Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
Gettinger, S. N.
Horn, L.
Ramalingam, S. S.
Spigel, D. R.
Paz-Ares, L.
Paik, P.
Reck, M.
Reckamp, K.
Mazieres, J.
Stinchcombe, T.
Lynch, M.
Brahmer, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S631 - S631
[33] Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Lima, Ellias Abreu
Sales, Paulo Guilherme
Vilaca, Israel
Perillo, Fernanda
Almeida, Flavia
Martins, Graziella
Goncalves, Mariana
Toledo, Joseane
Giovani, Poliana
Silva, Wania
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1443 - S1444
[34] Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
Lal, R.
Hillerdal, G. N.
Shah, R. N. H.
Crosse, B.
Thompson, J.
Nicolson, M.
Vikstrom, A.
Potter, V. A.
Visseren-Grul, C.
Lorenzo, M.
D'yachkova, Y.
Bourayou, N.
Summers, Y. J.
[J]. LUNG CANCER, 2015, 89 (02) : 154 - 160
[35] Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC).
Mehra, Ranee
Turaka, Aruna
Meyer, Joshua E.
Egleston, Brian L.
Tanvetyanon, Tawee
Pinder, Mary Colleen
Dilling, Thomas J.
Williams, Charles C.
Gray, Jhanelle Elaine
Shirai, Keisuke
Alpaugh, R. Katherine
Riordan, Debbie
Somaiah, Neeta
Shah, Prashant C.
Scott, Walter Joseph
Simon, George R.
Borghaei, Hossein
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[36] Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
Horn, L.
Brahmer, J.
Reck, M.
Borghaei, H.
Spigel, D. R.
Steins, M.
Ready, E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Burgio, M. A.
Fayette, J.
Gettinger, S. N.
Harbison, C. T.
Li, A.
Finckenstein, F. G.
Paz-Ares, L.
[J]. ANNALS OF ONCOLOGY, 2015, 26 : 125 - 125
[37] A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
Verma, S.
Malik, P. S.
Kalra, K.
Singh, V.
Kumar, S.
Khurana, S.
Pushpam, D.
Jain, D.
Gupta, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S130 - S131
[38] Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results
Patel, J. D.
Hensing, T. A.
Villafor, V.
Hart, E.
Bonomi, P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[39] Impact of Reflex Testing on Pathology Based Molecular Testing in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Marmarelis, M.
Berman, A.
Scholes, D.
Thompson, J.
Doucette, A.
Gabriel, P.
Bauml, J.
Singh, A.
Cohen, R.
Litzky, L.
Mcgrath, C.
Feldman, M.
Langer, C.
Carpenter, E.
Aggarwal, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1157 - S1157
[40] Immunotherapy in patients with advanced stage non-squamous (non-Sq) non-small cell lung cancer (NSCLC) with activating genetic mutations: Single institution retrospective study.
Khaddour, Leila
Singh, Sunny R. K.
Rybkin, Igor I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →